Enter Title

HER2 Names

100

Herceptin generic name

trastuzamab

200

capecitabine brand name

Xeloda

300

fam-trastuzamab deruxtecan-nxki brand name

Enhertu

400

Kadcyla generic name

ado-trastuzamab emtansine

500

neratinib brand name

Nerlynx

Percentages

100

Reduction in risk of new brain lesions in patients who received Tukysa in HER2CLIMB

45%

200

Percentage of patients with HER2+ mBC who develop brain metastases in the second line

42%

300

Percentage of patients with HER2+ mBC who may develop brain metastases during the course of their disease

~50%

400

Percentage of HER2CLIMB patients that had visceral metastases at baseline

74%

500

Percentage in the Tukysa arm of HER2CLIMB who received subsequent anticancer treatment

77%

Clinical Trials

100

Demonstrating a median PFS of 28.8 months vs. 6.8 months in the comparator arm

DESTINY-Breast 03 (Phase 3)

200

Number of patients studied in DEBBRAH (phase 2)

21

300

Approved in February 2013, this study examined the trial agent vs. the comparator arm of lapatinib + capecitabine

EMILIA (phase 3)

400

369 (70%) of patients in this study presented with visceral metastases

DESTINY-Breast03 (phase 3)

500

The 12-month OS rate was 90.3% in this study

DESTINY-Breast12 (phase 3b/4)

Misc.

100

Following treatment with ENHERTU, _______ is the only regimen with compelling data for 3L brain metastases

HER2CLIMB

200

There are no data from pivotal trials for either _______ or _______ use after ENHERTU

KADCYLA, TUKYSA

300

This was the Confirmed ORR for Tukysa + trastuzamab + capcitabine vs. 22.8% with placebo + trastuzamab + capecitabine in the HER2CLIMB trial

40.6%

400

Median time from metastatic diagnosis to the development of brain metastases

~1 year

500

Tukysa demonstrated ___% reduction in risk of disease progression or death in patients with brain metastases

52%